Home > Boards > Stock Clubs > Long-Term > Coffee Sipping Big Board Stocks

Health Venture Unveils Name, Site -- WSJ

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
EZ2 Member Profile
Followed By 203
Posts 219,231
Boards Moderated 1
Alias Born 03/31/01
160x600 placeholder
Fidelity National Information Services Falls 7% Following 2Q Earnings
By Maria Armental
Pollard Banknote Secures Four-Year Contract with Maryland Lottery
STOXX Europe 50 Index Ends 0.32% Higher at 3581.90 -- Data Talk
Oersted AS's Onshore Business Unit CEO Steps Down
DAX Ends 0.09% Lower at 15555.08 -- Data Talk
EURO STOXX 50 Index Ends Flat at 4117.95 -- Data Talk
OLB Group Shares Rise on New Cryptocurrency Subsidiary
CAC 40 Index Ends 0.72% Higher at 6723.81 -- Data Talk
STOXX Europe 600 Index Ends 0.20% Higher at 465.38 -- Data Talk
FTSE 100 Index Ends 0.34% Higher at 7105.72 -- Data Talk
U.S. Crude-Oil Stockpiles Likely to Fall in DOE Data, Analysts Say
FTSE 100 Closes Higher After Positive Corporate Earnings
Starbucks On Pace for Longest Losing Streak Since February 2020 -- Data Talk
Fidelity National Down Over 8%, on Pace for Largest Percent Decrease Since March 2020 -- Data Talk
Top Company News of the Day
Unemployment Rate Seen Ticking Down to 5.7% -- Data Week Ahead
Moderna Gets FDA Fast Track Designation for Respiratory Syncytial Virus Vaccine
Abbott Gets FDA Approval for AI-Powered Imaging Tech
Activision Blizzard Names New Leaders for Blizzard Entertainment
L3Harris to Sell Electron-Devices Unit to Arlington Capital for $185 Million
Hancock Jaffe Laboratories Gets Breakthrough Device Designation for VenoValve
Marinus Pharmaceuticals Submits NDA to FDA for Seizure Treatment
Eli Lilly Narrows 2021 Sales Guidance; Earnings Guidance Steady
Novartis Gets FDA Approval to Proceed With Trials for Muscular Atrophy Treatment
L3Harris Stronger Segment Growth Drives 2Q Rise in Profit
Eli Lilly 2Q Sales Grow, With Lift From Covid-19 Antibody Sales
Stocks Rise, BP Advances After Results
Translate Bio Shares Surge on Takeover by Sanofi
DuPont Raises Full-Year Sales Outlook
DuPont 2Q Sales, Profit Grow on Broad Industrial Recovery
FTSE Gains, Pound to Rise if BOE Cements 2022 Rate Rise Bets
EZ2   Thursday, 03/07/19 07:21:27 AM
Re: BullNBear52 post# 120310
Post # of 120365 
Health Venture Unveils Name, Site -- WSJ

DOW JONES & COMPANY, INC. 2:47 AM ET 3/7/2019
Symbol Last Price Change
AMZN 1668.95down 0 (0%)
BRK/A 301375down 0 (0%)
JPM 103.72down 0 (0%)
UNH 239.07down 0 (0%)
QUOTES AS OF 04:00:00 PM ET 03/06/2019

This article is being republished as part of our daily reproduction of WSJ.com articles that also appeared in the U.S. print edition of The Wall Street Journal (March 7, 2019).

The high-profile health-care venture launched last year by Amazon.com Inc.(AMZN), Berkshire Hathaway Inc.(BRK/A) and JPMorgan Chase & Co.(JPM) finally has a name: Haven.

The new company, which has formally released almost no information about its plans, is also unveiling a website, which includes a letter from Chief Executive Atul Gawande, a well-known writer and surgeon. But the site appears to add little new detail on the venture's plans. Some information already had emerged in an ongoing court case filed by UnitedHealth Group Inc.(UNH) against one of its own former employees, who is now working for Haven.

Dr. Gawande's letter says that Haven "will create new solutions and work to change systems, technologies, contracts, policy and whatever else is in the way of better health care."

Haven, which was incorporated in Delaware as a limited liability company formally named Tcorp62018, will initially focus on the employees of the three founding companies, according to a screenshot from the new website, echoing company officials' earlier testimony. The site says that "in time, we intend to share our innovations and solutions to help others."

In its suit, UnitedHealth's(UNH) Optum health-services unit has argued that the venture is a potential rival, and officials from the venture have said they aren't competing with Optum.

The website reiterates that Haven isn't meant to generate profits and will "reinvest any surplus back into our work."

The company says it will focus on priorities including improved access to primary care, simplifying insurance coverage and making prescription drugs more affordable -- all issues that were previously highlighted in court testimony. In a Q&A on the site, in answer to a question about whether Haven will look to replace patients' existing doctors and insurance companies, the company says it is "interested in working with clinicians and insurance companies to improve the overall health care system."

Write to Anna Wilde Mathews at anna.mathews@wsj.com

Corrections & Amplifications An earlier version of this article misspelled JPMorgan(JPM) as JPMorgen in the headline. (March 6, 2019)

(END) Dow Jones Newswires
Copyright (c) 2019 Dow Jones & Company, Inc.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences